Format
Sort by
Items per page

Send to

Choose Destination

Best matches for NAFLD berberine:

Search results

Items: 1 to 20 of 41

1.

Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway.

Zhu X, Bian H, Wang L, Sun X, Xu X, Yan H, Xia M, Chang X, Lu Y, Li Y, Xia P, Li X, Gao X.

Free Radic Biol Med. 2019 Jun 18;141:192-204. doi: 10.1016/j.freeradbiomed.2019.06.019. [Epub ahead of print]

PMID:
31226399
2.

Berberine prevents non-alcoholic steatohepatitis-derived hepatocellular carcinoma by inhibiting inflammation and angiogenesis in mice.

Luo Y, Tian G, Zhuang Z, Chen J, You N, Zhuo L, Liang B, Song Y, Zang S, Liu J, Yang J, Ge W, Shi J.

Am J Transl Res. 2019 May 15;11(5):2668-2682. eCollection 2019.

3.

Berberine promotes the recruitment and activation of brown adipose tissue in mice and humans.

Wu L, Xia M, Duan Y, Zhang L, Jiang H, Hu X, Yan H, Zhang Y, Gu Y, Shi H, Li J, Gao X, Li J.

Cell Death Dis. 2019 Jun 13;10(6):468. doi: 10.1038/s41419-019-1706-y.

4.

Berberine Ameliorates High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Rats via Activation of SIRT3/AMPK/ACC Pathway.

Zhang YP, Deng YJ, Tang KR, Chen RS, Liang S, Liang YJ, Han L, Jin L, Liang ZE, Chen YN, Yang QH.

Curr Med Sci. 2019 Feb;39(1):37-43. doi: 10.1007/s11596-019-1997-3. Epub 2019 Mar 13.

PMID:
30868489
5.

Berberine attenuates hepatic oxidative stress in rats with non-alcoholic fatty liver disease via the Nrf2/ARE signalling pathway.

Deng Y, Tang K, Chen R, Nie H, Liang S, Zhang J, Zhang Y, Yang Q.

Exp Ther Med. 2019 Mar;17(3):2091-2098. doi: 10.3892/etm.2019.7208. Epub 2019 Jan 28.

6.

Berberine alleviates nonalcoholic fatty liver induced by a high-fat diet in mice by activating SIRT3.

Xu X, Zhu XP, Bai JY, Xia P, Li Y, Lu Y, Li XY, Gao X.

FASEB J. 2019 Jun;33(6):7289-7300. doi: 10.1096/fj.201802316R. Epub 2019 Mar 8.

PMID:
30848932
7.
8.

Inhibition of CCL19 benefits non‑alcoholic fatty liver disease by inhibiting TLR4/NF‑κB‑p65 signaling.

Zhao J, Wang Y, Wu X, Tong P, Yue Y, Gao S, Huang D, Huang J.

Mol Med Rep. 2018 Nov;18(5):4635-4642. doi: 10.3892/mmr.2018.9490. Epub 2018 Sep 14.

PMID:
30221732
9.

Nutraceutical Approach to Non-Alcoholic Fatty Liver Disease (NAFLD): The Available Clinical Evidence.

Cicero AFG, Colletti A, Bellentani S.

Nutrients. 2018 Aug 23;10(9). pii: E1153. doi: 10.3390/nu10091153.

10.

Berberine alleviates hepatic lipid accumulation by increasing ABCA1 through the protein kinase C δ pathway.

Liang H, Wang Y.

Biochem Biophys Res Commun. 2018 Apr 6;498(3):473-480. doi: 10.1016/j.bbrc.2018.03.003. Epub 2018 Mar 2.

PMID:
29505790
11.

Berberine induces miR-373 expression in hepatocytes to inactivate hepatic steatosis associated AKT-S6 kinase pathway.

Li CH, Tang SC, Wong CH, Wang Y, Jiang JD, Chen Y.

Eur J Pharmacol. 2018 Apr 15;825:107-118. doi: 10.1016/j.ejphar.2018.02.035. Epub 2018 Feb 22.

12.

Natural products berberine and curcumin exhibited better ameliorative effects on rats with non-alcohol fatty liver disease than lovastatin.

Feng WW, Kuang SY, Tu C, Ma ZJ, Pang JY, Wang YH, Zang QC, Liu TS, Zhao YL, Xiao XH, Wang JB.

Biomed Pharmacother. 2018 Mar;99:325-333. doi: 10.1016/j.biopha.2018.01.071.

PMID:
29353208
13.

Amelioration of Intestinal Barrier Dysfunction by Berberine in the Treatment of Nonalcoholic Fatty Liver Disease in Rats.

Li D, Zheng J, Hu Y, Hou H, Hao S, Liu N, Wang Y.

Pharmacogn Mag. 2017 Oct-Dec;13(52):677-682. doi: 10.4103/pm.pm_584_16. Epub 2017 Nov 13.

14.

Natural Active Compounds from Plant Food and Chinese Herbal Medicine for Nonalcoholic Fatty Liver Disease.

Liu Q, Zhu L, Cheng C, Hu YY, Feng Q.

Curr Pharm Des. 2017;23(34):5136-5162. doi: 10.2174/1381612823666170918120643. Review.

PMID:
28925892
15.

Berberine ameliorates fatty acid-induced oxidative stress in human hepatoma cells.

Sun Y, Yuan X, Zhang F, Han Y, Chang X, Xu X, Li Y, Gao X.

Sci Rep. 2017 Sep 12;7(1):11340. doi: 10.1038/s41598-017-11860-3.

16.

Mode of action of berberine on lipid metabolism: a new-old phytochemical with clinical applications?

Sahebkar A, Watts GF.

Curr Opin Lipidol. 2017 Jun;28(3):282-283. doi: 10.1097/MOL.0000000000000409. Review. No abstract available.

PMID:
28459766
17.

Hepatic AMP Kinase as a Potential Target for Treating Nonalcoholic Fatty Liver Disease: Evidence from Studies of Natural Products.

Xu G, Huang K, Zhou J.

Curr Med Chem. 2018;25(8):889-907. doi: 10.2174/0929867324666170404142450. Review.

PMID:
28393690
18.

Comparison of dietary polyphenols for protection against molecular mechanisms underlying nonalcoholic fatty liver disease in a cell model of steatosis.

Rafiei H, Omidian K, Bandy B.

Mol Nutr Food Res. 2017 Sep;61(9). doi: 10.1002/mnfr.201600781. Epub 2017 Apr 20.

PMID:
28317281
19.

Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease.

Zhao L, Cang Z, Sun H, Nie X, Wang N, Lu Y.

BMC Endocr Disord. 2017 Feb 28;17(1):13. doi: 10.1186/s12902-017-0165-7.

20.

Activation of AMPK by berberine induces hepatic lipid accumulation by upregulation of fatty acid translocase CD36 in mice.

Choi YJ, Lee KY, Jung SH, Kim HS, Shim G, Kim MG, Oh YK, Oh SH, Jun DW, Lee BH.

Toxicol Appl Pharmacol. 2017 Feb 1;316:74-82. doi: 10.1016/j.taap.2016.12.019. Epub 2016 Dec 28. Erratum in: Toxicol Appl Pharmacol. 2017 Apr 1;320:73.

PMID:
28038998

Supplemental Content

Loading ...
Support Center